RA Capital Management’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-5,914,252
| Closed | -$4.13M | – | 63 |
|
|
2023
Q1 | $4.13M | Hold |
5,914,252
| – | – | 0.09% | 56 |
|
|
2022
Q4 | $5.32M | Hold |
5,914,252
| – | – | 0.11% | 59 |
|
|
2022
Q3 | $35.5M | Hold |
5,914,252
| – | – | 0.76% | 40 |
|
|
2022
Q2 | $24.5M | Hold |
5,914,252
| – | – | 0.65% | 41 |
|
|
2022
Q1 | $22.5M | Hold |
5,914,252
| – | – | 0.49% | 52 |
|
|
2021
Q4 | $26.6M | Hold |
5,914,252
| – | – | 0.47% | 53 |
|
|
2021
Q3 | $27.6M | Hold |
5,914,252
| – | – | 0.38% | 56 |
|
|
2021
Q2 | $41.7M | Hold |
5,914,252
| – | – | 0.67% | 49 |
|
|
2021
Q1 | $35M | Buy |
5,914,252
+1,232,394
| +26% | +$7.47M | 0.53% | 47 |
|
|
2020
Q4 | $21.6M | Hold |
4,681,858
| – | – | 0.3% | 56 |
|
|
2020
Q3 | $18.2M | Hold |
4,681,858
| – | – | 0.33% | 52 |
|
|
2020
Q2 | $135M | Hold |
4,681,858
| – | – | 2.62% | 9 |
|
|
2020
Q1 | $101M | Hold |
4,681,858
| – | – | 3.18% | 9 |
|
|
2019
Q4 | $92.1M | Hold |
4,681,858
| – | – | 2.79% | 11 |
|
|
2019
Q3 | $70.3M | Buy |
+4,681,858
| New | +$72.6M | 4.19% | 8 |
|
RA Capital Management's STSA Position: Q2 2023 in Review
RA Capital Management sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q2 2023, closing a stake of 5,914,252 shares — an estimated $4.13M sold.
RA Capital Management first reported a position in STSA in Q3 2019 and held it in 15 quarters. The position peaked at $135M in Q2 2020. 0 funds tracked by Wall St. Rank hold STSA as of Q2 2023.
- RA Capital Management reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- RA Capital Management sold 5,914,252 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $4.13M.
- RA Capital Management first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 15 quarters.
- RA Capital Management's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $135M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q2 2023.
Based on RA Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.